ストックスクリーナーアプリを入手
416.81
2.01%
8.20
前日終値:
$408.61
開ける：
$407.36
24時間の取引高:
1.05M
Relative Volume:
0.59
時価総額：
$106.87B
収益：
$11.39B
当期純損益:
$3.64B
株価収益率:
29.79
EPS:
13.9904
ネットキャッシュフロー:
$3.50B
1週間 パフォーマンス:
+2.21%
1か月 パフォーマンス:
+7.66%
6か月 パフォーマンス:
-14.78%
1年 パフォーマンス:
-16.43%
1日の値動き範囲:
$406.76
$419.37
1週間の範囲:
$402.58
$419.37
52週間の値動き範囲:
$362.50
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
名前
Vertex Pharmaceuticals Inc
セクター
電話
(617) 341-6393
住所
50 NORTHERN AVENUE, BOSTON, MA
VRTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-25 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 開始されました | Raymond James | Mkt Perform |
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-12 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-19 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-09 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Perform |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-08-05 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 開始されました | Redburn Atlantic | Buy |
| 2024-04-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2024-02-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-02 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | ダウングレード | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-05-04 | 再開されました | Piper Sandler | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Hold |
| 2023-01-17 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-06-01 | アップグレード | Maxim Group | Hold → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-05-06 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 繰り返されました | JP Morgan | Overweight |
| 2022-01-27 | 繰り返されました | Morgan Stanley | Underweight |
| 2022-01-27 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-01-27 | 繰り返されました | Stifel | Hold |
| 2022-01-27 | 繰り返されました | Wolfe Research | Outperform |
| 2022-01-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-19 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | ダウングレード | Stifel | Buy → Hold |
| 2021-09-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-07-01 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-30 | 開始されました | Daiwa Securities | Outperform |
| 2020-11-30 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 開始されました | Bernstein | Outperform |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-07-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-31 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-09-03 | アップグレード | Goldman | Neutral → Buy |
| 2019-08-01 | ダウングレード | Needham | Buy → Hold |
| 2019-05-23 | 再開されました | Citigroup | Buy |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | In-line |
| 2019-03-26 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | ダウングレード | Maxim Group | Buy → Hold |
すべてを表示
Vertex Pharmaceuticals Inc (VRTX) 最新ニュース
A Closer Look at Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Stability - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - sharewise.com
Vertex Pharmaceuticals (VRTX) Advances Povetacicept for Kidney D - GuruFocus
Goldman Sachs Cuts Vertex Pharmaceuticals Price Target to $603 From $624, Buy Rating Kept - MarketScreener
Vertex Pharmaceuticals (VRTX) Advances Development of Key Therap - GuruFocus
Vertex Pharma Says FDA Grants Rolling Review of Povetacicept Application for IgA Nephropathy - MarketScreener
Vertex announces progress in povetacicept development program and presentation of new data at American Society of Nephrology kidney week - MarketScreener
Vertex Announces Progress In Povetacicept Development Program And Presentation Of New Data At American Society Of Nephrology Kidney Week - TradingView
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week - Via TT
Vertex Pharmaceuticals: Commercial Pipeline Is Stronger Than What The Market Thinks - Yahoo Finance
Custom watchlist performance reports with Vertex Pharmaceuticals IncorporatedEarnings Risk Summary & Weekly Top Gainers Alerts - newser.com
Vertex Pharmaceuticals Incorpor (VRTX) Stock Forecasts - Yahoo
Earnings Preview: What To Expect From Vertex Pharmaceuticals' Report - MSN
Vertex redeploys CF windfall into high-risk frontiers - The Pharma Letter
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
Will Vertex Pharmaceuticals Incorporated bounce back from current supportJuly 2025 Final Week & Fast Gain Stock Tips - newser.com
Can Vertex Pharmaceuticals Incorporated stock resist sector downturnsWeekly Trade Review & Entry Point Confirmation Signals - newser.com
2 Unstoppable Growth Stocks to Buy During a Market Crash - The Motley Fool
Best Biotech Stocks To Follow NowOctober 10th - MarketBeat
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Lobbying Update: $1,110,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Quiver Quantitative
11 Newly Overvalued Stocks this Week - Morningstar
Griffin Asset Management Inc. Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock Analysis: Navigating a Promising 18% Upside in the Biotech Leader - DirectorsTalk Interviews
Is Vertex Pharmaceuticals Incorporated stock a safe investment in uncertain marketsProfit Target & Weekly Market Pulse Alerts - newser.com
Promising Biotech Stocks To Follow NowOctober 11th - MarketBeat
Why Vertex Pharmaceuticals Incorporated (VX1) stock signals breakout potentialJuly 2025 Technicals & AI Powered Buy/Sell Recommendations - newser.com
Apollon Wealth Management LLC Purchases 4,630 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Meritage Portfolio Management Decreases Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Stake Increased by Vanguard Personalized Indexing Management LLC - MarketBeat
US Bancorp DE Acquires 1,324 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Commerzbank Aktiengesellschaft FI Has $4.39 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Galvin Gaustad & Stein LLC - MarketBeat
Aberdeen Group plc Has $128.20 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Callan Family Office LLC - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Blair William & Co. IL - MarketBeat
Vertex Pharma announces new share buybacks worth up to $4B - MSN
Vertex Pharmaceuticals (VRTX): Analyst Rating Update from Morgan Stanley | VRTX Stock News - GuruFocus
Pharma Compliance Trends Revealed at PCC West - BioXconomy
Recovering from injury, Boston Celtics star Jayson Tatum laces up for Vertex campaign - PRWeek
Evercore ISI Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Quantitative breakdown of Vertex Pharmaceuticals Incorporated recent moveWeekly Investment Recap & Technical Analysis for Trade Confirmation - newser.com
Vertex Pharmaceuticals Incorporated stock daily chart insightsJuly 2025 Setups & Risk Managed Investment Signals - newser.com
Trifecta Capital Advisors LLC Buys 802 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Optas LLC Lowers Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vontobel Holding Ltd. Decreases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Weiss Ratings Reiterates "Hold (C+)" Rating for Vertex Pharmaceuticals (NASDAQ:VRTX) - MarketBeat
Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market - Yahoo Finance
Vertex Pharmaceuticals Experiences Evaluation Revision Amid Mixed Market Indicators - Markets Mojo
Is Vertex Stock Poised for Growth After Positive CRISPR Therapy Trial Results in 2025? - Yahoo Finance
RBC Capital Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals Inc (VRTX) 財務データ
収益
当期純利益
現金流量
EPS
0.12%
0.50%
大文字化:
|
ボリューム (24 時間):